Patterns of disease recurrence influenced by hematogenous tumor cell dissemination in patients with cervical carcinoma of the uterus

The presence of isolated tumor cells (ITC) in the bone marrow at the time of primary diagnosis indicates an increased risk for subsequent development of distant metastases in various solid tumors. This study evaluates the prevalence and prognostic significance of ITC in patients with primary carcinoma of the cervix uteri.

[1]  Paul Symonds,et al.  Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis , 2001, The Lancet.

[2]  S. Braun,et al.  The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence , 2001, Cancer.

[3]  J. Dunst,et al.  Adjuvante Radio-und Chemotherapie beim Zervixkarzinom , 2001, Zentralblatt fur Gynakologie.

[4]  S. Braun,et al.  Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Braun,et al.  Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Jacobs,et al.  Molecular quantification and mapping of lymph-node micrometastases in cervical cancer , 2001, The Lancet.

[7]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[8]  P. Grigsby,et al.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[10]  M. Heatley.  Cytokeratin 10/13, 14, 7, 8, and 18 in invasive squamous cell carcinoma and adenocarcinoma of the uterine cervix. , 1999, Journal of clinical pathology.

[11]  J. Shepherd,et al.  FIGO staging of gynecologic cancer , 1999 .

[12]  T. Brümmendorf,et al.  Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Donnez.  Today's treatments: medical, surgical and in partnership , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  C. V. D. van de Velde,et al.  Micrometastases and survival in stage II colorectal cancer. , 1998, The New England journal of medicine.

[15]  T. Iwasaka,et al.  Adjuvant Chemotherapy After Radical Hysterectomy for Cervical Carcinoma: A Comparison With Effects of Adjuvant Radiotherapy , 1998, Obstetrics and gynecology.

[16]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[17]  A. van Dalen,et al.  Epitope Specificity of 30 Monoclonal Antibodies against Cytokeratin Antigens: The ISOBM TD5-1 Workshop , 1998, Tumor Biology.

[18]  L. Sobin,et al.  TNM classification of malignant tumors, fifth edition (1997) , 1997, Cancer.

[19]  M. Nair,et al.  Cytokeratins and the evaluation of tumor differentiation in squamous lesions of the uterine cervix. , 1997, General & diagnostic pathology.

[20]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[21]  K. Pantel,et al.  Prognostic significance of bone marrow micrometastases in patients with gastric cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Pearcey,et al.  Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cell lines. , 1996, International journal of radiation oncology, biology, physics.

[23]  A. Hart,et al.  Prognostic significance of serum fragments of cytokeratin 19 measured by Cyfra 21-1 in cervical cancer. , 1994, Gynecologic oncology.

[24]  M. Gallee,et al.  Expression of cytokeratin 10, 13, and involucrin as prognostic factors in low stage squamous cell carcinoma of the uterine cervix , 1994, Cancer.

[25]  I. Kjønniksen,et al.  Microenvironment revisited: Time for reappraisal of some prevailing concepts of cancer metastasis , 1994, Journal of cellular biochemistry.

[26]  C. Bucana,et al.  Organ-specific modulation of steady-state mdr gene expression and drug resistance in murine colon cancer cells. , 1994, Journal of the National Cancer Institute.

[27]  H. Heinzl,et al.  Prognostic value of cytokeratins and carcinoembryonic antigen expression in primary surgically treated cervical cancer. , 1994, Anticancer research.

[28]  T. Susini,et al.  Schauta‐Amreich vaginal hysterectomy and Wertheim‐Meigs abdominal hysterectomy in the treatment of cervical cancer: A retrospective analysis , 1993, American journal of obstetrics and gynecology.

[29]  G. Schlimok,et al.  Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients , 1992, The Lancet.

[30]  A. Kriplani,et al.  Bone metastases in the patients of carcinoma cervix. , 1992, Indian journal of cancer.

[31]  O. Fodstad,et al.  Site-dependent differences in sensitivity of LOX human melanoma tumors in nude rats to dacarbazine and mitozolomide, but not to doxorubicin and cisplatin. , 1992, Cancer research.

[32]  F. Abdul-Karim,et al.  Bone metastasis from gynecologic carcinomas: a clinicopathologic study. , 1990, Gynecologic oncology.

[33]  J. Shepherd.  Revised FIGO staging for gynaecological cancer , 1989, British journal of obstetrics and gynaecology.

[34]  G. Steel,et al.  Induction and rejoining of DNA double-strand breaks in human cervix carcinoma cell lines of differing radiosensitivity. , 1988, Radiation research.

[35]  B. Geiger,et al.  Cytokeratin expression in squamous metaplasia of the human uterine cervix. , 1986, Differentiation; research in biological diversity.

[36]  H Stein,et al.  Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[37]  R. Moll,et al.  Cytokeratins of normal epithelia and some neoplasms of the female genital tract. , 1983, Laboratory investigation; a journal of technical methods and pathology.

[38]  Webb Mj,et al.  Wertheim hysterectomy: a reappraisal. , 1979 .

[39]  M. J. Webb,et al.  Wertheim Hysterectomy: A Reappraisal , 1979, Obstetrics and gynecology.

[40]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[41]  G. Viale,et al.  Cytokeratin-immunoreactive cells of human lymph nodes and spleen in normal and pathological conditions , 2005, Virchows Archiv A.

[42]  J. Shepherd,et al.  FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[43]  K. Nasu,et al.  Serum levels of cytokeratin 19 fragments in cervical cancer. , 1996, Gynecologic and obstetric investigation.

[44]  R. Holle,et al.  Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[45]  K. Pantel,et al.  Detection and characterization of residual disease in breast cancer. , 1994, Journal of hematotherapy.

[46]  H. Nakano,et al.  Bone metastasis from cervix cancer. , 1989, Gynecologic oncology.

[47]  R. Moll.  Diversity of cytokeratins in carcinomas. , 1987, Acta histochemica. Supplementband.

[48]  O. Beahrs.  The American Joint Committee on Cancer. , 1984, Bulletin of the American College of Surgeons.

[49]  D.,et al.  Regression Models and Life-Tables , 2022 .